Cytomx Therapeutics, Inc. · NASDAQ:CTMX
Cytomx Therapeutics — Wells Fargo 21st Annual Healthcare Conference 2026
31 slides from Cytomx Therapeutics's conference presentation, Sep 8, 2026
Slide 1: Unmasking Advances in Oncology
Unmasking Advances in Oncology Wells Fargo 21st Annual Healthcare Conference Dr. Sean McCarthy, CEO and Chairman September 8, 2026 © 2026 CytomX Therapeutics, Inc. 1
Slide 2: Legal Disclaimer
Legal Disclaimer This presentation (including any oral commentary that accompanies this presentation) contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements ot
Slide 3: PROBODY Therapeutic Design
PROBODY® Therapeutic Design Right Target, Right Tumor, Right Effector Mechanism PROBODY® Platform: Leading the field of masked therapeutics Clinical Programs: • Varsetatug masetecan (EpCAM PROBODY ® Topo-1 ADC)* for Colorectal Cancer and EpCAM-expressing tumors • CX-801 (PROBODY ® IFN-α2b) for Melan
Slide 4: Varseta-M is the only EpCAM-Directed ADC in Development
Varseta-M is the only EpCAM-Directed ADC in Development Granted FDA Fast Track Designation for R/R mCRC in August 2026 Varseta-M Efficacy in Late-Line CRC1 • Confirmed ORR of 20% at 8.6 mg/kg and 32% at 10 mg/kg • Preliminary PFS of 6.8 months at 8.6 mg/kg and 7.1 months at 10 mg/kg • High EpCAM exp
Slide 5: Varseta-M Development Plan Continues to Broaden in CRC and Additional EpCAM-Expressing GI Indications
Varseta-M Development Plan Continues to Broaden in CRC and Additional EpCAM-Expressing Gastrointestinal Indications Product Candidate(s) Indication(s) Phase 1 / 2 Phase 3 / Registrational • Phase 1 Update Expected by end of 2026 Varseta-M Monotherapy 3L+ metastatic CRC • Potential Registrational Stu
Slide 6: Varsetatug masetecan (Varseta-M)
Varsetatug masetecan (Varseta-M)* A Novel EpCAM-Directed ADC Focused on Colorectal Cancer (CRC) and Gastrointestinal Tumors *Formerly known as CX-2051 © 2026 CytomX Therapeutics, Inc. 6
Slide 7: Antibody Drug Conjugates are Transforming Cancer Care
Antibody Drug Conjugates are Transforming Cancer Care Varseta-M brings the promise of ADCs to colorectal cancer Varseta-M * PROBODY® ADC Nectin-4 / Bladder HER2 / Breast, Lung** EpCAM / CRC Seagen/Pfizer Daiichi/Astra Zeneca CytomX Therapeutics FRα / Ovarian TROP2 / Breast Immunogen/AbbVie Immunomed
Slide 8: Colorectal Cancer Remains One of the Biggest Unmet Needs in Oncology
Colorectal Cancer Remains One of the Biggest Unmet Needs in Oncology 2nd leading cause of ~1.9M patients per year, 5-year survival rate of cancer death increasing to 3M by 2040 13% in mCRC worldwide Sources: World Health Organization, interactive data; Biller and Schrag, 2021, JAMA; American Cancer
Slide 9: Varseta-M Potential to Address a Large Patient Population in CRC
Varseta-M has the Potential to Address a Large Patient Population due to Broad and Consistent EpCAM Expression in CRC By 2035 U.S. CRC Diagnosed Incidence Estimated to be 165K Patients Annually Metastatic CRC (mCRC) 1L mCRC >$30 Billion TAM ~90K U.S. Patients 2L mCRC >$12 Billion TAM ~50K U.S. Patie
Slide 10: Varsetatug masetecan: A Novel EpCAM Targeting PROBODY ADC
Varsetatug masetecan: A Novel EpCAM Targeting PROBODY ® ADC The Right Target, The Right Payload DAR 8 TAL-CAMP59 Varseta-M L-ala-L-ala-L-ala (TAL) cleavable linker S O O O H H N N O N N N O H H O O O NH CAMP59 Maleimidocaproyl O N F N O CAMP66 HO O • EpCAM is abundant in CRC but previously undruggab
Slide 11: The Current Standard of Care in 3L+ Metastatic CRC Is Highly Inadequate
The Current Standard of Care in 3L+ Metastatic CRC Is Highly Inadequate Current therapies have limited survival benefit Treatment ORR DCR Median PFS Median OS Treatment Line (%) (%) (months) (months) Fruquintinib1 3L/4L+ 2% 56% 3.7 7.4 Regorafenib2 3L/4L+ 1% 41% 2.0 6.4 Trifluridine/tipiracil3 3L/4L
Slide 12: Varseta-M Development Strategy
Varseta-M Development Strategy © 2026 CytomX Therapeutics, Inc. 12
Slide 13: Varseta-M is a Differentiated, Potential First-in-Class ADC
Varseta-M is a Differentiated, Potential First-in-Class ADC Positioned to Address a Broad EpCAM+ Patient Population Unlocking Multiple Layers of Value Creation 3 2 Potential to 1 Expand into 1L/2L mCRC additional EpCAM+ potential through indications Goal for Varseta-M chemotherapy 1st FDA approval a
Slide 14: Broad Development Opportunity for Varseta-M in Metastatic CRC
Broad Development Opportunity for Varseta-M in Metastatic CRC Potential across the treatment paradigm as monotherapy and in combinations Varseta-M Combination Strategies to Varseta-M Late-Line Replace Chemotherapy Strategies 1st Line 2nd Line 3rd Line+ KRAS/NRAS/BRAF WT (50% of mCRC) FOLFOX / FOLFIR
Slide 15: Varseta-M Monotherapy Development in mCRC
Varseta-M Monotherapy Development in mCRC © 2026 CytomX Therapeutics, Inc. 15
Slide 16: Varseta-M Phase 1 Monotherapy Focused in Late-Line Metastatic CRC
Varseta-M Phase 1 Monotherapy Focused in Late-Line Metastatic CRC Data to inform potential registrational study in 3rd or 4th line mCRC Phase 1 Study: 113 Monotherapy Patients Enrolled • Phase 1 Dose Escalation (began April 2024); Dose Expansions (began May 2025); Dose Optimization (began October 20
Slide 17: Varseta-M Combinations in Earlier-Line mCRC
Varseta-M Combinations in Earlier-Line mCRC © 2026 CytomX Therapeutics, Inc. 17
Slide 18: Varseta-M Combination with Bevacizumab is Ongoing
Varseta-M Combination with Bevacizumab is Ongoing with Potential to Enable 3rd line CRC Development Varseta-M + Bevacizumab Varseta-M + Bevacizumab Phase 1 Dose Escalation in 3L+ mCRC1 Potential Later Phase Development* 3rd Line mCRC: Varseta-M Q2W + Bevacizumab Varseta-M + Bevacizumab vs. Lonsurf +
Slide 19: Planned Varseta-M Phase 1/2 Combination Study with Bevacizumab + 5-FU
Planned Varseta-M Phase 1/2 Combination Study with Bevacizumab + 5-FU Enables Potential Irinotecan Replacement in 1st and 2nd line mCRC Varseta-M + Bevacizumab + 5-FU Phase 2 Study Phase 1 Dose Escalation Phase 1 / 2 Study Enrollment in 2nd Line mCRC Varseta-M Q2W + Bevacizumab, 5-FU/leucovorin (BFF
Slide 20: Varseta-M in EpCAM+ Gastrointestinal Cancers
Varseta-M in EpCAM+ Gastrointestinal Cancers © 2026 CytomX Therapeutics, Inc. 20
Slide 21: Broadening the Varseta-M Program to EpCAM+ GI Indications
Broadening the Varseta-M Program to EpCAM+ GI Indications Patient enrollment to commence in Q3 2026 EpCAM Highly Expressed in US Incidence – Prioritized GI Cancers Prioritized GI Tumors1 ~130K Patients Diagnosed Annually BTC ~20K Gastric/GEJ* 85% ~50K 77% 55% 55% PDAC ~60K GEJ Gastric PDAC BTC *Incl
Slide 22: Varseta-M Monotherapy Cohort Expansions in GI Indications
Varseta-M Monotherapy Cohort Expansions in GI Indications with High Unmet Need Initiating in Q3 2026 Varseta-M Ph1 GI Expansions Phase 1 Study Overview Q3W Dose(s) N=~60 • Key Endpoints: – Safety, tolerability, PK – Efficacy: ORR, PFS • Key Inclusion Criteria Gastric / GEJ, 3L+ PDAC, 2-3L+ BTC, 2L+
Slide 23: Multiple Varseta-M Milestones Anticipated Over Next 12 to 18 Months
Multiple Varseta-M Milestones Anticipated Over Next 12 to 18 Months1 2026 2027 Program Q1 Q2 Q3 Q4 Q1 Q2 Phase 1 Phase 1 data update Expansion Data Varseta-M Monotherapy CRC Align with FDA on registrational study and potential registrational study start Varseta-M Bevacizumab Phase 1 Study Initial
Slide 24: CX-801 PROBODY IFNα-2b
CX-801 PROBODY® IFNα-2b A Novel Immunotherapy Focused in Melanoma © 2026 CytomX Therapeutics, Inc. 24
Slide 25: IFNα-2b is a Powerful Cancer Immunotherapy
IFNα-2b is a Powerful Cancer Immunotherapy With Ideal Properties to Combine with Checkpoint Inhibitor Therapy Why IFNα-2b? IFNα-2b Mechanism of Action IFNα stimulates • Kills cancer cells directly leading to immunogenic cell death IFNα stimulates Dendritic cells • Stimulates antigen presenting cells
Slide 26: CX-801: Dually-Masked, Conditionally Activated PROBODY IFNα2b
CX-801: Dually-Masked, Conditionally Activated PROBODY® IFNα2b CX-801 TARGET EFFECTOR Affinity Masking Validated, High Potential Target IFNα2b • Approved immunotherapy in • Dual-mechanism of action multiple tumors • Proven single agent activity Steric Masking • Enhanced anti-cancer activity in (Fc P
Slide 27: High Unmet Need in PD-1 Refractory Melanoma Patients
High Unmet Need in PD-1 Refractory Melanoma Patients CX-801 has potential to enhance responsiveness to checkpoint inhibitors Metastatic Melanoma Landscape Anti-PD-1 ± Anti-CTLA-4 or Anti-LAG3 1, 2, 3, 4, 5 1L CX-801 Development Opportunities in BRAF WT (~50%) BRAF Mutations (~50%) Melanoma BRAF inh.
Slide 28: Phase 1 Dose Escalation Designed to Assess CX-801 Clinical Profile
Phase 1 Dose Escalation is Designed to Assess CX-801 Clinical Profile as Monotherapy and in Combination with KEYTRUDA® Monotherapy Dose Escalation Combination Dose Escalation Focused in Advanced Melanoma CX-801 + KEYTRUDA® CX-801 DL 4 DL 5+ Currently enrolling CX-801 Initiated Combination DL Cleared
Slide 29: Milestones and Outlook
Milestones and Outlook © 2026 CytomX Therapeutics, Inc. 29
Slide 30: Multiple Milestones Anticipated Over Next 12 to 18 Months
Multiple Milestones Anticipated Over Next 12 to 18 Months1 2026 2027 Program Q1 Q2 Q3 Q4 Q1 Q2 Phase 1 Phase 1 data update Expansion Data Varseta-M Monotherapy CRC Align with FDA on registrational study and potential registrational study start Varseta-M Bevacizumab Phase 1 Study Initial safety & e
Slide 31: Unmasking Advances in Oncology
Unmasking Advances in Oncology September 2026 © 2026 CytomX Therapeutics, Inc. 31
CytomX Therapeutics — Wells Fargo 21st Annual Healthcare Conference 2026 on 6ix